How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide
NEJM Evidence · 2023
DOI: 10.1056/evide2300053 ↗Kurz gefasst
Editorial in der Zeitschrift NEJM Evidence, 2023. Verfasst von Zhuoer Xie und 1 weiteren Autor:innen. Beteiligte Einrichtung: Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to manage expectations for patients and providers alike.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
- Division of Hematologic Malignancies, The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore.
Zitieren
APA
Xie, Z., & DeZern, A. E. (2023). How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide. NEJM Evidence. https://doi.org/10.1056/evide2300053
Vancouver
Xie Z, DeZern AE. How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide. NEJM Evidence. 2023. doi:10.1056/evide2300053
BibTeX
@article{Xie2023,
author = {Xie, Zhuoer and DeZern, Amy E},
title = {How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide},
journal = {NEJM Evidence},
year = {2023},
doi = {10.1056/evide2300053}
}
EUVIMED